Michael Weinstein

In a report published Monday, JPMorgan analyst Michael Weinstein discussed Johnson & Johnson (NYSE: JNJ)'s upcoming first quarter report, scheduled for Tuesday, April 14. Weinstein noted that he is expecting a largely in-line quarter on the top line given an improved pharmaceutical...

Johnson & Johnson's (NYSE: JNJ) pharmaceuticals products may drive second-quarter results to just above Street views when it reports earnings next week, an analyst said Thursday. J.P. Morgan's Michael Weinstein said the segment is growing at an annual rate of 15 percent. But it'...

In a report published Wednesday, J.P. Morgan analyst Michael Weinstein reiterated a Neutral rating on Medtronic (NYSE: MDT), and raised the price target from $59.00 to $63.00. In the report, J.P. Morgan noted, “Medtronic reported solid 2Q results Tuesday, as revenues of $4.194B (+2.4%, +3.3% cc)...

In a report published Wednesday, J.P. Morgan analyst Michael Weinstein downgraded the rating on Edwards Lifesciences Corp. (NYSE: EW) from Neutral to Underweight, and lowered the price target from $64.00 to $62.00. In the report, J.P. Morgan noted, “We're lowering rating on shares of Edwards today...

In a report published Wednesday, J.P. Morgan analyst Michael Weinstein upgraded Tornier NV (NASDAQ: TRNX) from Neutral to Overweight, and raised the price target from $20.00 to $24.00. In the report, J.P. Morgan noted, “We are upgrading shares of Tornier from Neutral to Overweight as (1) the...

In a report published Monday, J.P. Morgan analyst Michael Weinstein reiterated an Overweight rating on HeartWare International (NASDAQ: HTWR). In the report, J.P. Morgan noted, “Overall, we view the CAP approval as a positive that should help to alleviate investor concerns about the DT data set...

In a report published on Wednesday, JP Morgan analyst Michael Weinstein raised the price target from $7.80 to $8.00 on Boston Scientific (NYSE: BSX) and reiterated a Neutral rating. In the report, JP Morgan stated, "Boston faces multiple challenges, in our view. First and foremost is a...

Analyst Michael Weinstein of JP Morgan maintains his "overweight" rating on Insulet Corp (NASDAQ: PODD), while raising his estimates for the company. The target price for PODD is set to $16. According to JP Morgan, Insulet reported its Q4 results ahead of the estimates on better than expected cost...

Analyst Michael Weinstein of JP Morgan maintains his "overweight" rating on Medtronic (NYSE: MDT). According to JP Morgan, Medtronic is likely to face increased competition in the kyphoplasty market due to the entry of CareFusion (NYSE: CFN) into the market. “CareFusion’s aggressiveness is apt to...

Analyst Michael Weinstein of JP Morgan upgrades ev3 Inc (NASDAQ: EVVV) from “neutral” to “overweight.” The price target for EVVV has been raised from $15 to $19. There is upside to the consensus estimates for ev3’s top and bottom line results for 4Q09 and 2010. The atherectomy business, which had...